Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
2.440
+0.160 (7.02%)
At close: Aug 7, 2026, 4:00 PM EDT
2.437
-0.003 (-0.13%)
After-hours: Aug 7, 2026, 7:35 PM EDT
Acumen Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
61
Market Cap
176.24M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| LENZ Therapeutics | 20.99M |
| Alector | 18.42M |
| Caribou Biosciences | 11.20M |
| Innate Pharma | 10.57M |
| Korro Bio | 3.84M |
| Milestone Pharmaceuticals | 1.78M |
| YD Bio | 510.36K |
ABOS News
- 2 days ago - Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026 - GlobeNewsWire
- 24 days ago - Acumen presents new findings at AAIC conference - TheFly
- 24 days ago - Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC®) 2026 - GlobeNewsWire
- 4 weeks ago - Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC®) 2026 - GlobeNewsWire
- 7 weeks ago - JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform - Business Wire
- 7 weeks ago - Acumen nominates two development candidates in EBD program - TheFly
- 7 weeks ago - Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer's Disease - GlobeNewsWire
- 3 months ago - Acumen Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts